Oravax and Genomma Lab Press Conference

Oramed announced the formation of a 50/50 joint venture between Genomma Lab (www.genommalab.com/en/) and Oramed’s majority-owned subsidiary Oravax Medical Inc. (www.ora-vax.com) to develop and commercialize Oravax’s oral COVID-19 vaccine candidate in Mexico. Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, GenommaLab Chairman, will hold a joint press event today, Thursday, November 18, 2021, at 11:00 am EST.To view the press event: https://us02web.zoom.us/webinar/register/WN_QTGUI13dTdmWdUFKrg_Tbg

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

– Millions of people in the region could benefit from the COVID-19 vaccine candidate- faster, easier, without the cold chain: The Oravax Oral Vaccine – The new partnership builds on the respective strengths of Oravax Medical and Genomma Lab to create compelling value for both companies and their stakeholders – Press conference with Nadav Kidron, […]

Join our mailing list

Skip to content